


Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

## Seminars in Oncology

journal homepage: [www.elsevier.com/locate/seminoncol](http://www.elsevier.com/locate/seminoncol)

### Biographies of the authors

#### Management of Early Breast Cancer in Patients Bearing Germline BRCA Mutations

##### Marie-Daphné t'Kint de Roodenbeke



Marie-Daphné t'Kint, MD, is a medical oncologist and head of the Oncogenetic Clinic at the Jules Bordet Institute in Brussels (Belgium). She earned her medical degree from the Université Libre de Bruxelles (ULB) in 2005 and then studied medical oncology with a focus on breast cancer. She trained at the ULB Center of Human Genetics for four years and got a master's degree in oncogenetics from the Institut Curie in Paris (France) in 2014. Her academic efforts have centered on developing and promoting oncogenetic aspects as a part of cancer treatment by training multidisciplinary oncologic teams and encouraging studies on the oncogenetic aspect of tumors. She is also involved in the development of the specific follow-up for “very-high-risk patients” in the prevention clinic.

##### Noam Pondé

Dr. Noam Pondé is a medical oncologist that specializes in breast cancer and clinical research. He is a former Fellow of clinical research at Institut Jules Bordet, Brussels Belgium and is currently practicing at AC Camargo Cancer Center in Sao Paulo, Brazil.

##### Laurence Buisseret



Laurence Buisseret, MD, PhD, is a medical oncologist at the Institut Jules Bordet, Brussels, Belgium. She earned a medical degree from the Université Libre de Bruxelles (ULB), Belgium, in 2007 and then trained in medical oncology with a focus on breast cancer. In 2017, she obtained a PhD in the field of immune-oncology in breast cancer. During her PhD training, she worked as a basic research fellow at the Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CR-CHUM), Canada, in a laboratory specialized in the design of targeted therapies using immune strategies in preclinical models and translational research in immuno-oncology. Her clinical and laboratory research focuses on cancer immunotherapy and in she is involved in the development of therapeutic strategies to strengthen anti-tumor immunity in breast cancer.

##### Martine J. Piccart



Martine J. Piccart, MD, PhD, is an honorary professor of oncology at the Université Libre de Bruxelles (ULB) and scientific director at the Jules Bordet Institute (Brussels/Belgium). Earning her medical degrees at ULB and oncology qualifications in New York and London, she is also a member of the Belgian Royal Academy of Medicine. She held presidencies of the European CanCer Organisation (ECCO), the European Organisation for the Research and Treatment of Cancer (EORTC), the European Society for Medical Oncology (ESMO) and served on the American Society of Clinical Oncology Board (ASCO). Presently she is a member of the Board of the American Association for Cancer Research (AACR) which nominated her as fellow of the AACR Academy in 2013.

Throughout her career, Prof. Piccart has been honoured with numerous prestigious awards for her research contributions, including the David A. Karnofsky Memorial Award in recognition of innovative clinical research and developments that have changed the way oncologists think about the general practice of oncology (2013, ASCO, Chicago, USA) and most recently, the 2018 Prix Leopold Griffuel for translational and clinical research delivered by the

“Association pour la Recherche sur le Cancer” in France and the KNAW Bob Pinedo Cancer Care Award in November 2018 in Amsterdam, Netherlands.

An accomplished clinician and scientist, Prof. Piccart is author or co-author of over 520 publications in peer-reviewed journals.

---

### **Risk-based approaches for optimizing treatment in HER2-positive early stage breast cancer**

#### **Lauren Chiec**



Lauren Chiec, MD, is a second-year Hematology and Oncology fellow at McGaw Medical Center of Northwestern University in Chicago, Illinois. She earned her medical degree from the University of Cincinnati College of Medicine. She subsequently completed her residency in Internal Medicine, as well as a fellowship in Hospice and Palliative Medicine, both at Northwestern. She is currently serving as a chief fellow, and is particularly interested in supportive oncology research and quality improvement.

---

#### **Ami Shah**



Ami Shah, MD, is a breast medical oncologist at the Robert H Lurie Comprehensive Cancer Center of Northwestern University. In addition to focusing on patient care, she participates in clinical and translational research. She is specifically investigating circulating tumor biomarkers including circulating tumor cells and circulating tumor DNA to understand and treat advanced breast cancer. She is interested in heterogeneity of HER2 and how it is reflected in circulating biomarkers.

---

### **Systemic Therapy for Metastatic HER2-Positive Breast Cancer**

#### **Philip Bredin**



Dr. Philip Bredin, MB BCH BAO, MRCPI is a second year medical oncology fellow on the Higher Specialist Training programme of the Royal College of Physicians of Ireland. He studied medicine at University College Cork in Ireland and graduated with Honours in 2013. He completed his residency at Eastern Health in Melbourne, Australia on the Physician Training programme of the Royal Australasian College of Physicians. During this time Dr Bredin developed a passion for medical oncology, presenting his research at multiple international forums including the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Annual Scientific Meeting and the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. He has specialised in medical oncology since returning to Ireland in 2018. His current research interests include breast cancer, gastrointestinal cancers and prostate cancer.

---

#### **Janice Walshe**



Janice Walshe, MD is a Clinical Professor in Medical Oncology specialising in breast cancer in St Vincent's University Hospital, Ireland. She earned her medical degree from National University of Ireland, Galway in 1997 and completed her specialist training in the Mater Misericordiae Hospital, Dublin while gaining a masters in Molecular Medicine at Trinity College, Dublin. She completed her Fellowship in the National Cancer Institute, Bethesda, Maryland where her focus was novel approaches in Her-2 positive locally advanced and metastatic breast cancer. She returned to Ireland in 2006 where she is a member of Cancer Trials Ireland Research Group ensuring access to novel agents and research opportunities for Irish women affected by breast cancer. She was a member of the ASCO Scientific Committee in triple negative breast cancer from 2013-2015. She is also a senior lecturer at University College Dublin and Trinity College Dublin. Her research has been presented at numerous international meetings. She has authored several peer reviewed publications and served on the editorial board of several oncology journals.

---

**Neelima Denduluri**

Dr. Neelima Denduluri earned her medical degree from the Louisiana State University Medical Center, where she served as President of the American Medical Student Association. Upon graduation she received the “Exemplar of Desirable Attitudes of the Physician Towards His Patients” award, which is bestowed upon one graduating senior. She completed her Internal Medicine residency at Georgetown University Medical Center. During her fellowship at the National Cancer Institute, she was honored with the distinction of serving as Chief Fellow. She later served as Assistant Clinical Investigator and Staff Physician at NCI before joining Virginia Cancer Specialists. Dr. Denduluri remains highly involved in the local community by participating in community outreach, speaking to support groups, and volunteering at the Arlington Free Clinic since 1999. She has consistently been named as a Top Doctor in Northern Virginia Magazine and Washingtonian magazine, and she has been featured in both local and national media for her expertise in breast cancer. Dr. Denduluri is also the Cancer Committee Chairman at Virginia Hospital and is a steering committee member for NAPBC accreditation for the Reinsch Pierce Family Center for Breast Health. Dr. Denduluri continues to be active in medical education, currently serving as Clinical Assistant Professor at Georgetown University Medical Center.

**Management of ER positive metastatic breast cancer****Richard S. Finn**


Dr. Richard S. Finn is a Professor of Clinical Medicine in the Division of Hematology/ Oncology at the UCLA David Geffen School of Medicine and Director of the Signal Transduction Program in the Jonsson Comprehensive Cancer Center at UCLA.

He currently splits his time between patient care and laboratory and clinical research. His research interests lie in the development of molecular targeted agents and biomarkers in liver cancer and breast cancer. Dr Finn has served as principal and sub-investigator in trials exploring the use of targeted therapies in breast and hepatocellular cancers. He has a particular interest in identifying predictive markers of response to novel therapeutics. His work has been published in journals such as the New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Lancet Oncology, Cancer Research, Clinical Cancer Research, Hepatology, Cancer Cell and elsewhere. Dr Finn has also given oral presentations at major meetings including American Society of Clinical Oncology (ASCO), European Cancer Conference (ECCO/ ESMO), and the American Association of Cancer Research (AACR) and others. An active cancer researcher, he has been involved in the development of several novel therapeutics in cancer medicine. He has brought several practice changing advances to cancer medicine. With Dr Dennis Slamon, he led the approval of palbociclib (Ibrance), the first CDK 4/6 inhibitor in cancer medicine, from pre-clinical development to global registration.

Dr Finn is a member of ASCO, American Association of Cancer Research (AACR) and the European Society of Medical Oncology (ESMO). He is also on the editorial board of Clinical Cancer Research.

**Nicholas McAndrew**

Dr. Nicholas McAndrew is a breast cancer oncologist at the David Geffen School of Medicine of the University of California, Los Angeles. Dr. McAndrew received his medical degree as well as a Master of Science in Clinical Epidemiology from the Perelman School of Medicine at the University of Pennsylvania, and completed both his internal medicine residency and his hematology/oncology fellowship at the Hospital of the University of Pennsylvania. Dr. McAndrew is a principal investigator of multiple ongoing breast cancer clinical trials. His research is focused on the development of new therapies in breast cancer, as well as in using biomarkers to help predict response to therapy.

**Landmark Trials in the Medical Oncology Management of Early Stage Breast Cancer****Whitney Hensing**

Whitney Hensing, MD, MSCR is a second year fellow in the divisions of Hematology/Oncology at Washington University in St. Louis. She completed medical training at the University of Kansas School of Medicine and also earned a Master of science degree in clinical research. She completed Internal Medicine residency training at Washington University in St. Louis. She is interested in breast cancer research and clinical trials.

---

**Cesar A. Santa-Maria**

Cesar A. Santa-Maria, MD, MSCI is a breast medical oncologist within the Johns Hopkins Women's Malignancies Program. Dr. Santa-Maria completed his oncology training at Johns Hopkins, and has been focused on caring for patients with breast cancer since then. His research interest is in developing new types of treatment for patients with breast cancer using immunotherapy.

---

**Lindsay L. Peterson**

Lindsay L. Peterson, MD, MSCR is an Assistant Professor at Washington University School of Medicine. She completed her residency and fellowship at University of Texas in San Antonio. She obtained her MSCR at the Medical University of South Carolina. She is a breast oncologist whose research centers on improving outcomes in breast cancer patients through lifestyle interventions, including diet and exercise. She is the site PI for multiple phase III breast cancer clinical trials as well as investigator-initiated trials of lifestyle modification in breast cancer.

---

**Jennifer Y. Sheng**

Jennifer Y. Sheng, MD, is an Assistant Professor in the Department of Oncology at the Johns Hopkins University School of Medicine. She completed her residency at Temple University Hospital and her fellowship at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. Her research addresses the needs of breast cancer patients, especially improving quality of life and addressing comorbidity in breast cancer survivors, promptly detecting sequela of therapy, enhancing patient education and furthering symptom management in breast cancer patients.

---